Follow the Pundits
Tag: Baker Bros
Madrigal, BeiGene, and Biotech Alpha: Inside the “Gene-ius” Kingmakers of Baker Bros. 2025
Biotech Jedi at work. Baker Bros’ 2025 victory lap shows how Madrigal, BeiGene, and ruthless conviction turned science into serious alpha.
Baker Bros Are Bullish — Can Kodiak Kill the Bears?
When the sharpest biotech investors on the planet deploy $60 million, it’s worth paying attention. Kodiak Sciences is a high-risk, high-reward retinal biotech with late-stage trials, real institutional backing, and binary outcomes ahead. Fun, factual, and unapologetically speculative.
ACADIA Pharmaceuticals: Biotech Powerhouse Baker Bros Still Believes. Should You Buy In?
Biotech heavyweight Baker Bros still owns over 25% of ACADIA Pharmaceuticals (ACAD), and the stock is heating up. With expanding revenue, a rich CNS pipeline, and smart money backing it, is this the comeback story investors have been waiting for?
Best Hedge Funds 2025: Top Quants, Activists, and High-Return Managers
This article lists some of the most successful hedge funds based on the quality of their management, track record, key strategic focus, risk management, fee structure, and other criteria. Hedge funds follow various strategies to offer investors a compelling, but risky investment alternative. Investing with one requires a high minimum investment and specific wealth profile (high net worth, high-income generation threshold) from accredited investors. Hedge funds charge (approx.) a 2% management and 20% performance fee. The idea or hope is that they are worth it.